Rapport Therapeutics Q2 FY26 net loss widens to $56.6 million; R&D expense more than doubled to $51.4 million
RAPP•Cash position and runway
Cash, cash equivalents and short-term investments fell to $436.1 million; runway is projected into the second half of 2029.
Clinical program updates
The RAP-219 Phase 3 focal onset seizures program started, with FOCUS 1 and FOCUS 2 enrolling.
Bipolar mania Phase 2 topline data are expected in October 2026.
Q2 net loss widens as R&D spending rises
Rapport Therapeutics posted a Q2 2026 net loss of $56.6 million, widening from $26.7 million a year earlier.
R&D expense more than doubled to $51.4 million, driven by higher clinical-development and pipeline progression costs.
SG&A rose 38.24% to $9.4 million on costs tied to business growth.
